硼替佐米治疗晚期抗体介导的肾移植排斥反应的随机试验
结果显示 eGFR 斜率组间差异 0.5 ml/min/1.73m²/年(95%CI -4.8~5.8,P=0.86),无显著差异;24 个月 mGFR、2 年移植物存活、蛋白尿、DSA 及病理分子表型均无显著差异,但硼替佐米组出现胃肠道和血液学毒性。
要点
- 硼替佐米未能延缓晚期 ABMR 患者的 GFR 下降。
- 硼替佐米未改善组织学、分子学特征或降低 DSA。
- 硼替佐米与胃肠道和血液学毒性相关。
核心结论
- 本试验未能证明硼替佐米可预防 GFR 丢失、改善组织学或分子学疾病特征或降低 DSA,尽管存在显著毒性。
研究设计与样本
- 硼替佐米每周期 1.3 mg/m2 静脉给药,第 1、4、8、11 天,共两周期。
- 患者来自 741 例横断面筛查,移植后中位时间 5.0 年,19 例有移植前 DSA 记录。
主要发现
- eGFR 斜率(主要终点)组间差异为 0.5 ml/min/1.73m2/年(95%CI -4.8~5.8),无统计学显著性(P=0.86)。
- 24 个月中位实测 GFR:硼替佐米组 33 vs 安慰剂组 42 ml/min/1.73m2(P=0.31)。
- 2 年移植物存活:81% vs 96%(P=0.12)。
- 尿蛋白浓度、DSA 水平及 24 个月随访活检的形态学或分子排斥表型均无显著差异。
- 硼替佐米与胃肠道和血液学毒性相关。
临床怎么用
- 不推荐使用硼替佐米治疗晚期 ABMR 以延缓 GFR 下降或改善病理。
- 晚期 ABMR 的新疗法需经系统临床试验验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-specific antibody (DSA)-positive ABMR. Forty-four DSA-positive kidney transplant recipients with characteristic ABMR morphology (median time after transplant, 5.0 years; pretransplant DSA documented in 19 recipients), who were identified on cross-sectional screening of 741 patients, were randomly assigned to receive bortezomib (n=21) or placebo (n=23). The 0.5-ml/min per 1.73 m2 per year (95% confidence interval, -4.8 to 5.8) difference detected between bortezomib and placebo in eGFR slope (primary end point) was not significant (P=0.86). We detected no significant differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 versus 42 ml/min per 1.73 m2; P=0.31), 2-year graft survival (81% versus 96%; P=0.12), urinary protein concentration, DSA levels, or morphologic or molecular rejection phenotypes in 24-month follow-up biopsy specimens. Bortezomib, however, associated with gastrointestinal and hematologic toxicity. In conclusion, our trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity. Our results reinforce the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.
引用
- Eskandary F, Regele H, Baumann L, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2017. PMID: 29242250. doi:10.1681/ASN.2017070818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。